The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia
The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia
复制标题
DOI：
10.1007/s00428-008-0710-x
复制
发表时间：
2009-02-01
期刊：
影响因子：
3.5
通讯作者：
Capella, Carlo
中科院分区：
文献类型：
--
作者：
La Rosa, Stefano;Franzi, Francesca;Capella, Carlo
腺泡细胞癌（ACC）是一种罕见的胰腺癌，可能很难与其他实体非腺癌肿瘤区分。诊断取决于腺泡分化的证明，用识别各种胰腺酶的抗体获得，虽然特异性不同，但显示出不同的敏感性。BCL 10蛋白的C-末端部分显示与羧基酯水解酶（CEH）同源，所述羧基酯水解酶是由胰腺腺泡细胞产生的酶。我们研究了C-末端BCL 10单克隆抗体在ACC诊断中的有用性。我们检查了正常胰腺和不同的胰腺肿瘤，包括ACC，混合性腺泡内分泌癌，导管腺癌，粘液性，浆液性，实性假乳头状和内分泌肿瘤。此外，各种正常组织和胃食管粘膜的胰腺化生的情况下，异位胰腺的情况下，胃肠道内分泌肿瘤，唾液腺和乳腺腺泡细胞癌，胃腺癌和无腺泡分化，肝细胞癌进行了研究。BCL 10免疫反应性与CEH相同，仅限于正常和异位胰腺、胰腺化生和ACC的腺泡细胞。抗BCL 10抗体在检测ACC和胰腺化生方面比针对其他胰酶的抗体更敏感。我们建议使用BCL-10抗体诊断胰腺肿瘤，并在胃肠道肿瘤和化生病变中怀疑腺泡分化。
Acinar cell carcinoma (ACC) is a rare pancreatic cancer which may be difficult to distinguish from other solid nonadenocarcinoma tumors. The diagnosis depends on the demonstration of acinar differentiation, obtained with antibodies recognizing various pancreatic enzymes that, although specific, show different sensitivity. The C-terminal portion of the BCL10 protein shows homology with carboxyl ester hydrolase (CEH), an enzyme produced by pancreatic acinar cells. We investigated the usefulness of a C-terminal BCL10 monoclonal antibody in the diagnosis of ACCs. We examined normal pancreases and different pancreatic tumors including ACCs, mixed acinar-endocrine carcinomas, ductal adenocarcinomas, mucinous, serous, solid pseudopapillary, and endocrine neoplasms. In addition, various normal tissues and cases of pancreatic metaplasia of the gastroesophageal mucosa, cases of ectopic pancreas, gastrointestinal endocrine tumors, salivary and breast acinic cell carcinomas, gastric adenocarcinomas with and without acinar differentiation, and hepatocellular carcinomas were studied. BCL10 immunoreactivity paralleled that of CEH and was restricted to acinar cells of normal and ectopic pancreas, of pancreatic metaplasia, and of ACCs. The anti-BCL10 antibody was more sensitive in detecting ACCs and pancreatic metaplasia than antibodies directed against other pancreatic enzymes. We suggest using BCL10 antibody for diagnosing pancreatic tumors and whenever an acinar differentiation is suspected in gastrointestinal neoplastic and metaplastic lesions.